TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00057577
Drug: Medications
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. All recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
Study: NCT02580006
Drug: EPORON
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration subcutaneously
Study: NCT02580006
Drug: EPREX
Normalized name: Eprex
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration subcutaneously
Study: NCT01760980
Drug: Reference product (A) Aromasin (Exemestane)
Normalized name: Aromasin Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromasin tablets will be administered under fasting conditions on two occasions
Study: NCT04179162
Drug: Bacillus Calmette-Guérin (BCG)
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive once-weekly intravesical BCG therapy (TICE strain, 50 mg) at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6(+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days).
Study: NCT02691494
Drug: Placebo for Estradiol/Norethindrone Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT02691494
Drug: Estradiol/Norethindrone Acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
Study: NCT00189878
Drug: Methotrexate (drug)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 10 to 15 mg weekly for 8 weeks
Study: NCT00189878
Drug: placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-6 placebo capsules - identical to capsules containing methotrexate
Study: NCT00236197
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Study: NCT02157337
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg (PO) once daily for 6 days
Study: NCT01568229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral administration
Study: NCT01103830
Drug: Eurartesim™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
Study: NCT01103830
Drug: Riamet®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
Study: NCT06238856
Drug: SLIT™ Amikacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin administered via the Pari LC STAR™ nebulizer.
Study: NCT06238856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized saline.
Study: NCT03249558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
Study: NCT01967251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil placebo-matching tablets
Study: NCT05943990
Drug: GSK3845097
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3845097 was administered.
Study: NCT05943990
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered as lymphodepleting chemotherapy.
Study: NCT04193176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered twice daily as a placebo oral tablet matching gefapixant
Study: NCT02096380
Drug: One cycle TPF induction chemotherapy for NPC
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2.
Study: NCT02446990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
Study: NCT00534586
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
Study: NCT00918398
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg iv infusion, single dose, 4 hours infusion
Study: NCT00918398
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: 514 mg oral solution, single dose
Study: NCT00918398
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
Study: NCT00918398
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
Study: NCT03160573
Drug: ClōSYS® Unflavored Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03160573
Drug: ClōSYS® Flavored Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01829763
Drug: injection botox
Normalized name: onabotulinumtoxinA Injection [Botox]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00707369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
Study: NCT02016885
Drug: glycopyrrolate, 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycopyrrolate Topical Wipes, 1.0%
Study: NCT02016885
Drug: glycopyrrolate, 2.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycopyrrolate Topical Wipes, 2.0%
Study: NCT02016885
Drug: glycopyrrolate, 3.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycopyrrolate Topical Wipes, 3.0%
Study: NCT02016885
Drug: glycopyrrolate, 4.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycopyrrolate Topical Wipes, 4.0%
Study: NCT02653560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01307033
Drug: MK-0954A
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
Study: NCT01307033
Drug: MK-954H
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
Study: NCT01307033
Drug: Placebo to MK-0954A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet to match MK-0954A, once daily
Study: NCT01257893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
Study: NCT00678574
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily by mouth for 2-3 months.
Study: NCT04187690
Drug: Jin-shui Huan-xian granule placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.
Study: NCT01307033
Drug: Placebo to MK-954H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet to match MK-954H, once daily
Study: NCT04551586
Drug: ACH-0145228: Immediate Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACH-0145228 (240 milligrams) will be administered orally on Day 1.
Study: NCT04551586
Drug: ACH-0145228: Powder-in-capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACH-0145228 (240 milligrams) will be administered orally on Day 1.
Study: NCT01507103
Drug: cyclophosphamide (CPA)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
Study: NCT01140932
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 days of corticosteroids treatment (prednisolone 37,5 mg/day)
Study: NCT01582555
Drug: saline nasal irrigation alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
Study: NCT03987685
Drug: Oratopo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
Study: NCT03822715
Drug: standard of care aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care aromatase inhibitors
Study: NCT02605967
Drug: Investigator choice of chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
Study: NCT01740518
Drug: polyethylene glycol, ascorbic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different solutions for bowel preparation
Study: NCT00555087
Drug: Testosterone Undecanoate and/or PDE-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
Study: NCT04573478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01122368
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT02662582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT03258593
Drug: Vicineum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
Study: NCT03258593
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.
Study: NCT02512237
Drug: ARX788
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARX788, an antibody drug conjugate
Study: NCT03932071
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03656614
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of saline 0.9%.
Study: NCT01026428
Drug: Safinamide + Levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
Study: NCT03165695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
Study: NCT01219920
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
Study: NCT01080547
Drug: XELOX Chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XELOX chemotherapy
Study: NCT02355509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills are given instead of acarbose in this group
Study: NCT03484195
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 150 mg/m\^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m\^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m\^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m\^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)
Study: NCT00069953
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During induction therapy, patients receive 650 mg/m\^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m\^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
Study: NCT01219920
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
Study: NCT00153790
Drug: PhosphoLean
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00635050
Drug: Doxil, Paclitaxel, Cyclophosphamide, Avastin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3 . Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin 15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.~Regimen B: Doxil 30 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3. Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.
Study: NCT01236456
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00104403
Drug: GW679769
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02197988
Drug: Exparel 1.33% (20ml Volume)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus Abdominis Plane Block
Study: NCT02197988
Drug: 0.125% bupivicaine with 2 mcg/ml Fentanyl.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic Epidural Anesthesia
Study: NCT01152385
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet administered twice daily during 4 months
Study: NCT01152385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered twice daily during 4 months
Study: NCT01475331
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cysts will be lavaged for 3-5 minutes with 80% EtOH
Study: NCT01475331
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysts will be lavaged for 3-5 minutes with normal saline
Study: NCT01475331
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
Study: NCT03359395
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
Study: NCT00100477
Drug: Mitozantrone
Normalized name: Mitozantrone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02144818
Drug: Ovitrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triggering of ovulation with Ovitrel
Study: NCT02059642
Drug: MG01CI (1400 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
Study: NCT02059642
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1400 mg administered orally once daily
Study: NCT02122185
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02122185
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.
Study: NCT01197300
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous infusion
Study: NCT01027754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
Study: NCT04632342
Drug: HL301 tablet 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Experimental group 1 : 2 tablets at once, twice a day~* Experimental group 2 : 2 tablets at once, three times a day
Study: NCT04632342
Drug: Placebo of HL301 tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets at once, three times a day
Study: NCT01629563
Drug: PGL4001 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGL4001 5 mg daily administration
Study: NCT01629563
Drug: PGL4001 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGL4001 10mg daily administration
Study: NCT00594308
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60mg/kg/day for two consecutive days (-7,-6).
Study: NCT01480765
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
Study: NCT01480765
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo intravenous infusion for 48 hours
Study: NCT03735901
Drug: IMP Levodopa 100mg/Carbidopa 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning.
Study: NCT03735901
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning.
Study: NCT01103830
Drug: Eurartesim™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
Study: NCT04421664
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
Study: NCT00001789
Drug: BG9588
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02534623
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004228
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00004228
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00004228
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00004228
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00004228
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00963885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po for 12 weeks
Study: NCT00963885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po for 24 weeks
Study: NCT00185614
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
Study: NCT04392362
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A vial of adenosine with 6mg
Study: NCT01386645
Drug: high glycemic index diet plus N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.